BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-11.11%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$7.07B
AUM Growth
+$7.07B
(-18%)
Cap. Flow
-$179M
Cap. Flow
% of AUM
-2.53%
Top 10 Holdings %
Top 10 Hldgs %
34.72%
Holding
187
New
10
Increased
58
Reduced
81
Closed
15
Top Buys
| 1 |
Intuitive Surgical
ISRG
|
$58.1M |
| 2 |
DexCom
DXCM
|
$51.7M |
| 3 |
Pfizer
PFE
|
$41.4M |
| 4 |
Harmony Biosciences
HRMY
|
$28.1M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
$25.4M |
Top Sells
| 1 |
Elevance Health
ELV
|
$98M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$85.7M |
| 3 |
AbbVie
ABBV
|
$47.7M |
| 4 |
Bristol-Myers Squibb
BMY
|
$46.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$42.9M |
Sector Composition
| 1 | Healthcare | 98.26% |
| 2 | Industrials | 0.38% |
| 3 | Energy | 0.03% |
| 4 | Communication Services | 0.01% |
| 5 | Technology | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ionis Pharmaceuticals
IONS
$6.8B
| $362M | 5.12% | 9,776,528 -141,545 | -1% | -$5.24M |
|
2
argenx
ARGX
$43.6B
| $350M | 4.94% | 933,803 -19,435 | -2% | -$7.28M |
|
|
3
Vertex Pharmaceuticals
VRTX
$100B
| $331M | 4.69% | 1,176,136 -304,117 | -21% | -$85.7M |
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $277M | 3.92% | 2,844,305 -179,146 | -6% | -$17.5M |
|
5
Moderna
MRNA
$9.37B
| $225M | 3.19% | 1,577,351 -61,998 | -4% | -$8.86M |
|
6
Incyte
INCY
$16.5B
| $211M | 2.98% | 2,773,377 -74,023 | -3% | -$5.62M |
|
|
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $191M | 2.7% | 3,349,379 -80,240 | -2% | -$4.58M |
|
|
8
Intuitive Surgical
ISRG
$170B
| $183M | 2.58% | 909,348 +289,280 | +47% | +$58.1M |
|
9
Abbott
ABT
$231B
| $171M | 2.42% | 1,573,807 -49,120 | -3% | -$5.34M |
|
10
UnitedHealth
UNH
$281B
| $155M | 2.19% | 302,044 -3,657 | -1% | -$1.88M |
|
11
Alnylam Pharmaceuticals
ALNY
$58.5B
| $154M | 2.18% | 1,058,186 -171,377 | -14% | -$25M |
|
12
Boston Scientific
BSX
$156B
| $143M | 2.03% | 3,850,171 -63,776 | -2% | -$2.38M |
|
|
13
Jazz Pharmaceuticals
JAZZ
$7.75B
| $143M | 2.02% | 917,907 +162,926 | +22% | +$25.4M |
|
|
AXNX
14
DELISTED
Axonics, Inc. Common Stock
AXNX
| $131M | 1.85% | 2,313,852 +264,647 | +13% | +$15M |
|
|
15
Elevance Health
ELV
$71.8B
| $101M | 1.42% | 208,500 -203,137 | -49% | -$98M |
|
16
Edwards Lifesciences
EW
$47.8B
| $96.1M | 1.36% | 1,010,627 +97,842 | +11% | +$9.3M |
|
|
SAGE
17
DELISTED
Sage Therapeutics
SAGE
| $96M | 1.36% | 2,973,178 -79,226 | -3% | -$2.56M |
|
18
Stryker
SYK
$150B
| $95M | 1.34% | 477,634 +37,409 | +8% | +$7.44M |
|
19
Danaher
DHR
$147B
| $92.3M | 1.3% | 364,036 +6,974 | +2% | +$1.77M |
|
|
RDUS
20
DELISTED
Radius Health, Inc.
RDUS
| $91.2M | 1.29% | 8,796,538 +477,824 | +6% | +$4.96M |
|
21
Agios Pharmaceuticals
AGIO
$2.19B
| $90.1M | 1.27% | 4,062,792 -66,500 | -2% | -$1.47M |
|
22
Arvinas
ARVN
$568M
| $89.4M | 1.26% | 2,124,276 -54,977 | -3% | -$2.31M |
|
23
Fate Therapeutics
FATE
$120M
| $88M | 1.24% | 3,550,086 -26,400 | -0.7% | -$654K |
|
24
Sarepta Therapeutics
SRPT
$1.78B
| $85.4M | 1.21% | 1,139,455 -11,704 | -1% | -$877K |
|
25
Becton Dickinson
BDX
$55.3B
| $84.6M | 1.2% | 342,982 -53,423 | -13% | -$13.2M |
|